Feature | May 19, 2015

Edwards Halts Enrollment in Fortis Transcatheter Mitral Valve Trial

Temporary pause in trial program due to possible issues with thrombus

Edwards, Fortis, transcatheter mitral valve, trial, halts enrollment

May 19, 2015 — Edwards Lifesciences announced it has temporarily halted its clinical trial of the Fortis mitral transcatheter heart valve. The company said that in consultation with trial investigators, it was decided to voluntarily implement a temporary pause on enrollment in its Fortis clinical program because of evidence of valve thrombosis. The company said the issue warrants additional investigation before restarting enrollment.

“We are working closely with the trial investigators and heart teams to gather additional information in this early study of transcatheter mitral valve replacement therapy,” the company said in a statement.

To date, the company said more than 20 patients globally have been implanted with the Fortis valve, all of whom had symptomatic mitral regurgitation and who were either compassionate cases or in one of their high-risk registries. While it is still very early in the program, the company anticipated that optimizing this therapy would be challenging and said it is continuing to learn which patients may benefit.

The Fortis transcatheter mitral valve features treated bovine pericardial tissue leaflets, a cloth-covered self-expanding frame designed to minimize pravalvular leak and an anatomical anchoring system. It is delivered using a transapical approach with a sheathless delivery system. The valve has paddles that fold out at the base and clip the native mitral valve leaflets to help anchor it. The first human trial began in August 2014 with centers in the United Kingdom, Canada and Switzerland.

The Fortis valve is not approved for sale in any country.

For more information: www.edwards.com

Related Content

Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology| January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology| January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology| November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology| November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology| November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Videos | Heart Valve Technology| November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Harpoon Mitral Valve Repair System data reported at TCT 2017
Feature | Heart Valve Technology| November 07, 2017
November 7, 2017 – A new study has found that a pioneering device to repair heart valves is safe and effective, and c
Videos | Heart Valve Technology| November 07, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, explains the current state o
Overlay Init